Foros de Conocimiento
medtronic PRODUCTOS
boston_scientific PRODUCTOS
TERUMO PRODUCTOS
Biotronik PRODUCTOS
Sirtex PRODUCTOS
Striker Neurovascular PRODUCTOS
BIOSENSORS PRODUCTOS

ABSTRACT


01 abril 2017

CATHETERIZATION & CARDIOVASCULAR INTERVENTIONS. Impacts of early cardiac catheterization for children with congenital heart disease supported by extracorporeal membrane oxygenation

Atsuko Kato MD, Mauro Lo Rito MD, Kyong‐Jin Lee MD, Christoph Haller MD, Anne Marie Guerguerian MD, PhD, FRCPC, Venkatesan Ben Sivarajan MD, MS, FRCPC, Osami Honjo MD, PhD

Background: Cardiac catheterization is often required for patients on extracorporeal membranous oxygenation (ECMO) support, though its efficacy remains unclear. This study aimed to assess the impact of catheterization on successful ECMO weaning.

01 abril 2017

CATHETERIZATION & CARDIOVASCULAR INTERVENTIONS. The first clinical experience with a novel directional coronary atherectomy catheter: Preliminary Japanese multicenter experience

Maoto Habara MD, Etsuo Tsuchikane MD, PhD, FSCAI, Kenya Nasu MD, FACC, Yoshihisa Kinoshita MD, Tomonori Yaguchi MD, Yoriyasu Suzuki MD, Hitoshi Matsuo MD, PhD, Mitsuyasu Terashima MD, Tetsuo Matsubara MD, Takahiko Suzuki MD

Aims: Despite development of drug eluting stents (DES), percutaneous coronary intervention (PCI) for bifurcation lesions using DES alone remains challenging. The aim of this study was to report on the initial clinical experience with a novel directional coronary atherectomy (DCA) catheter.

01 abril 2017

CATHETERIZATION & CARDIOVASCULAR INTERVENTIONS. Type 4a myocardial infarction: Incidence, risk factors, and long‐term outcomes

Xiaoyu Yang MD, Hector Tamez MD, MPH, Carol Lai MD, Kalon Ho MD, MSC, Donald Cutlip MD

Objectives: To assess the incidence of and outcomes related to periprocedural (Type 4a) myocardial infarction (MI) in a cohort of patients undergoing percutaneous coronary intervention (PCI) for stable coronary disease or non ST‐elevation acute coronary syndrome with stable or falling cardiac troponin levels.

01 abril 2017

CATHETERIZATION & CARDIOVASCULAR INTERVENTIONS. ORBIT II sub‐analysis: Impact of impaired renal function following treatment of severely calcified coronary lesions with the Orbital Atherectomy System

Michael S. Lee MD, Arthur C. Lee MD, Richard A. Shlofmitz MD, Brad J. Martinsen PhD, Nick J. Hargus PhD, Mahir D. Elder MD, Philippe Généreux MD, Jeffrey W. Chambers MD

Objectives: To investigate the safety and efficacy of the coronary Orbital Atherectomy System (OAS) to prepare severely calcified lesions for stent deployment in patients grouped by renal function.

01 abril 2017

CATHETERIZATION & CARDIOVASCULAR INTERVENTIONS. The incidence of slow flow after rotational atherectomy of calcified coronary arteries: A randomized study of low speed versus high speed

Kenichi Sakakura MD, Hiroshi Funayama MD, Yousuke Taniguchi MD, Yoshimasa Tsurumaki MD, Kei Yamamoto MD, Mitsunari Matsumoto MD, Hiroshi Wada MD, Shin‐ichi Momomura MD, Hideo Fujita MD

Objectives: The purpose of this randomized trial was to compare the incidence of slow flow between low‐speed and high‐speed rotational atherectomy (RA) of calcified coronary lesions.

01 abril 2017

CATHETERIZATION & CARDIOVASCULAR INTERVENTIONS. Long‐term outcomes of rotational atherectomy for the percutaneous treatment of chronic total occlusions

Lorenzo Azzalini MD, PhD, MSc, Rustem Dautov MD, PhD, Soledad Ojeda MD, PhD, Antonio Serra MD, PhD, Susanna Benincasa MD, Barbara Bellini MD, Francesco Giannini MD, Jorge Chavarría MD, Livia L. Gheorghe MD, Manuel Pan MD, PhD, Mauro Carlino MD, Antonio Colombo MD, Stéphane Rinfret MD, SM

Objectives. To study the long‐term outcomes of rotational atherectomy (RA) for chronic total occlusion (CTO) percutaneous coronary intervention (PCI).

01 abril 2017

CATHETERIZATION & CARDIOVASCULAR INTERVENTIONS. Comparison of acute expansion of bioresorbable vascular scaffolds versus metallic drug‐eluting stents in different degrees of calcification: An optical coherence tomography study

Jiang Ming Fam, Johannes N van Der Sijde, Antonios Karanasos, Cordula Felix, Roberto Diletti, Nicolas van Mieghem, Peter de Jaegere, Felix Zijlstra, Robert Jan van Geuns, Evelyn Regar

Objectives: The acute expansion of bioresorbable vascular scaffolds (BRS) and drug‐eluting stents (DES) in lesions with different extent of calcification was compared by Optical Coherence Tomography (OCT).

01 abril 2017

CATHETERIZATION & CARDIOVASCULAR INTERVENTIONS. Expansion in calcific lesions and overall clinical outcomes following bioresorbable scaffold implantation optimized with intravascular ultrasound

Hiroyoshi Kawamoto MD, Neil Ruparelia DPhil, mrcp, Azeem Latib MD, Tadashi Miyazaki MD, Katsumasa Sato MD, Akihito Tanaka MD, Toru Naganuma MD, Alessandro Sticchi MD, Alaide Chieffo MD, Mauro Carlino MD, Matteo Montorfano MD, Antonio Colombo MD

Objectives: This study aimed to investigate clinical outcomes following bioresorbable scaffold (BRS) optimized with intravascular ultrasound (IVUS), and furthermore expansion of BRS in calcific lesions.

01 abril 2017

CATHETERIZATION & CARDIOVASCULAR INTERVENTIONS. Relationship of mitral valve annulus plane and circumflex‐right coronary artery plane: Implications for transcatheter mitral valve implantation

Samir R. Kapadia MD, Amgad Mentias MD, Amr F. Barakat MD, Mohammad Q. Raza MD, Kanhaiya Lal Poddar MD, Cristian Baeza MD, Gabriel Maluenda MD, Jose Navia MD, Paul Schoenhagen MD, E. Murat Tuzcu MD

Aim: Transcatheter mitral valve implantation (TMVI) is a novel technology for patients with severe mitral valve disease but at high surgical risk. Imaging guidance during the procedure is critical for successful device deployment. Identification of the mitral annular plane (MAP) with fluoroscopy during the procedure is limited by lack of clearly defined landmarks. We hypothesized that a plane defined by left circumflex‐right coronary arteries (LCX‐RCA) would have a consistent relationship to MAP.

01 mayo 2017

CATHETERIZATION & CARDIOVASCULAR INTERVENTIONS. End‐stage renal disease and severe aortic stenosis: Does valve replacement improve one‐year outcomes?

Jose F. Condado MD, MS, Aneel Maini, Bradley Leshnower MD, Vinod Thourani MD, Jessica Forcillo MD, Chandan Devireddy MD, Kreton Mavromatis MD, Eric L. Sarin MD, James Stewart MD, Robert Guyton MD, Amy Simone PA, Patricia Keegan NP, Stamatios Lerakis MD, Peter C. Block MD, Vasilis Babaliaros MD

Background. Treatment for patients with end‐stage renal disease (ESRD) and severe aortic stenosis (AS) includes balloon aortic valvuloplasty (BAV), surgical (SAVR), or transcatheter (TAVR) aortic valve replacement. We compared outcomes among these strategies.

Utilizamos cookies propias para el correcto funcionamiento del sitio web y mejorar nuestros servicios. Pulse el botón Aceptar todas para aceptar su uso. Puede cambiar la configuración u obtener más información en nuestra Política de cookies o pulsando Modificar configuración.